Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tanvex BioPharmaTPE:6541 +0.83%47 Equity-to-Asset is 0.65 as of Jun. 2026, which is 8% below its 10-year median of 0.71. GuruFocus rates TPE:6541 with a GF Score™ of 47/100. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Tanvex BioPharma ranks worse than 53.9% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Tanvex BioPharma's Total Stockholders Equity for the quarter that ended in Jun. 2026 was NT$4,965.5 Mil. Tanvex BioPharma's Total Assets for the quarter that ended in Jun. 2026 was NT$7,634.8 Mil.
Therefore, Tanvex BioPharma's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.65.
The historical rank and industry rank for Tanvex BioPharma's Equity-to-Asset or its related term are showing as below:
TPE:6541'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.15 Med: 0.71 Max: 0.95
Current: 0.65
During the past 13 years, the highest Equity to Asset Ratio of Tanvex BioPharma was 0.95. The lowest was 0.15. And the median was 0.71.
TPE:6541's Equity-to-Asset is ranked worse than 53.9% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs TPE:6541: 0.65
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Tanvex BioPharma Equity-to-Asset Related Terms
Tanvex BioPharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Tanvex BioPharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Tanvex BioPharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a Equity-to-Asset of 0.65 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tanvex BioPharma and its competitors. This is near median its historical median of 0.71. Over the past decade, Tanvex BioPharma's Equity-to-Asset has ranged from 0.15 to 0.95. According to the industry distribution chart, Tanvex BioPharma ranks #761 out of 1412 companies in the Biotechnology industry, placing it in the top 53.9%.
Is Tanvex BioPharma's Equity-to-Asset too high?
Tanvex BioPharma's current Equity-to-Asset of 0.65 is near median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.95. The Biotechnology industry median Equity-to-Asset is 0.69. Tanvex BioPharma's value of 0.65 is 5.8% below this industry median. Based on the distribution chart, Tanvex BioPharma ranks #761 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #761 out of 1412 companies for Equity-to-Asset. This places Tanvex BioPharma in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Tanvex BioPharma's value of 0.65 is 5.8% below this benchmark. Historically, Tanvex BioPharma's own Equity-to-Asset has ranged from 0.15 to 0.95 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 0.69, Tanvex BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tanvex BioPharma's current Equity-to-Asset of 0.65 is 5.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tanvex BioPharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tanvex BioPharma's current Equity-to-Asset is 0.65, which is near median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Tanvex BioPharma (TPE:6541) has a current Equity-to-Asset of 0.65. The current Equity-to-Asset is 0.65, which is near median its 10-year median of 0.71 and 5.8% below the Biotechnology industry median of 0.69. Tanvex BioPharma's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Equity-to-Asset is 0.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
47GF Score
Get the complete analysis for TPE:6541
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
